MX2024005766A - Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas. - Google Patents

Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas.

Info

Publication number
MX2024005766A
MX2024005766A MX2024005766A MX2024005766A MX2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A
Authority
MX
Mexico
Prior art keywords
imidazo
crystalline
pharmaceutical compositions
pyridine compound
treating medical
Prior art date
Application number
MX2024005766A
Other languages
English (en)
Spanish (es)
Inventor
Benoit Robert
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2024005766A publication Critical patent/MX2024005766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2024005766A 2021-11-12 2022-11-11 Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas. MX2024005766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207942.0A EP4180428A1 (en) 2021-11-12 2021-11-12 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
PCT/US2022/049695 WO2023086564A1 (en) 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Publications (1)

Publication Number Publication Date
MX2024005766A true MX2024005766A (es) 2024-07-29

Family

ID=78617277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005766A MX2024005766A (es) 2021-11-12 2022-11-11 Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas.

Country Status (10)

Country Link
US (3) US11814383B2 (cg-RX-API-DMAC10.html)
EP (2) EP4180428A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543413A (cg-RX-API-DMAC10.html)
CN (1) CN118843624A (cg-RX-API-DMAC10.html)
AU (1) AU2022387516A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237156A1 (cg-RX-API-DMAC10.html)
IL (1) IL312625A (cg-RX-API-DMAC10.html)
MX (1) MX2024005766A (cg-RX-API-DMAC10.html)
TW (1) TW202334143A (cg-RX-API-DMAC10.html)
WO (1) WO2023086564A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067914B1 (en) * 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
AU2024273547A1 (en) * 2023-05-17 2025-12-04 Centrexion Therapeutics Corporation PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
MA40698A3 (fr) 2014-12-18 2020-01-31 Genzyme Corp Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk)
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
BR112022016901A2 (pt) * 2020-02-26 2022-12-06 Cullgen Shanghai Inc Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Also Published As

Publication number Publication date
TW202334143A (zh) 2023-09-01
US11814383B2 (en) 2023-11-14
US20240150352A1 (en) 2024-05-09
US12291528B2 (en) 2025-05-06
EP4180428A1 (en) 2023-05-17
JP2024543413A (ja) 2024-11-21
US20230151008A1 (en) 2023-05-18
US20250250274A1 (en) 2025-08-07
IL312625A (en) 2024-07-01
AU2022387516A1 (en) 2024-05-23
EP4430043A1 (en) 2024-09-18
EP4430043A4 (en) 2025-11-05
WO2023086564A1 (en) 2023-05-19
CA3237156A1 (en) 2023-05-19
CN118843624A (zh) 2024-10-25

Similar Documents

Publication Publication Date Title
CR20220537A (es) [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2
GEAP202416515A (en) Quinoline compounds as inhibitors of kras
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MX2010014233A (es) Compuestos quimicos 251.
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
TN2009000224A1 (en) Inhibitors of akt activity
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
TW200714604A (en) Substituted heterocycles and the uses thereof
MX2023012187A (es) Derivados de fosforo como nuevos inhibidores de sos1.
PH12021553248A1 (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
WO2009022185A3 (en) 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MY202884A (en) Compounds useful in hiv therapy
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof